On Wednesday, in the course of current trade, Shares of Automatic Data Processing (NASDAQ:ADP), climbed 1.76%, and is now trading at $ 84.62.
Automatic Data Processing, declared that Lhoist North America, a leading producer of lime, dolime and minerals, has expanded its use of ADP’s HCM technology and expertise to meet the company’s growing need for talent around the world.
Lhoist North America, an ADP client for more than 20 years, adds ADP Recruiting Administration to their existing ADP HCM solutions, counting benefits, time and labor administration, background screening services, i-9 compliance screening, tax filing, and payroll.
ADP Recruiting Administration supports the company’s talent acquisition efforts, providing an up-to-date solution that is accessible on a variety of mobile devices. This embrace of individuals’ needs for mobility enables top candidates to access the company’s website from anywhere, at any time, while giving hiring managers the ability to track candidate progress and access other information.
Automatic Data Processing, Inc., together with its auxiliaries, provides technology-based outsourcing solutions to employers worldwide. The company operates through Employer Services and Professional Employer Organization (PEO) Services segments.
During an Afternoon trade, Shares of Juno Therapeutics Inc (NASDAQ:JUNO), dipped - 0.39%, and is now trading at $ 61.90.
Juno Therapeutics, declared that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging clinical responses in patients with B-cell cancers. Clinical results will be presented in an oral presentation recently at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
“We are gaining important translational insights from the JCAR014 trial, and these data highlight the potential to meaningfully improve cell expansion and cell persistence in non-Hodgkin lymphoma (NHL) patients, in addition to more broadly in patients with different cancers across our portfolio of cellular immunotherapies,” said Mark Frohlich, M.D., Juno EVP of development and portfolio strategy. “We are encouraged by the early evidence that these improved in vivo properties are translating into improved efficacy for patients, and we will apply these and other learning’s to our multi-center trial for JCAR017 in NHL that we intend to start in the second half of 2015.”
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Shares of CIT Group Inc. (NYSE:CIT), during its Wednesday’s current trading session raised 1.69%, and is now trading at $ 47.42.
CIT Group, declared that CIT Corporate Finance, Healthcare offered a $29.5 million senior secured credit facility to Real Properties Health Facilities Corp. (RPHF), that will be used to consolidate existing real estate debt and for working capital purposes. RPHF operates 12 skilled nursing and assisted living facilities with about 1,000 accessible beds in Indiana, Kansas, Montana and Wisconsin. Lancaster Pollard, a specialty healthcare investment bank, advised RPHF as its placement agent for the financing. Financing was offered by CIT Bank, the U.S. commercial bank partner of CIT.
“This financing was extremely important to us as we consolidate our ownership and position ourselves for our future,” said Patricia Green, President and CEO, Real Properties Health Facilities Corp. “CIT’s expertise and experience in middle market healthcare financing was essential to us when choosing a lender.”
CIT Group Inc. operates as the holding company for CIT bank that provides commercial financing and leasing products; and a suite of savings options in the United States. Its Transportation & International Finance segment offers leasing and financing solutions to operators and suppliers in the aviation and railcar industries.
Finally, Kansas City Southern (NYSE:KSU), lost -0.29% Wednesday, hitting its highest level.
Kansas City Southern, declared that its U.S. partner, The Kansas City Southern Railway Company (KCSR), has reached a contract with Sasol Chemicals (USA) LLC (Sasol) for the construction and long-term lease of a storage-in-transit (SIT) rail yard to support Sasol’s new ethane cracker and derivatives project in Lake Charles, La. In addition to building the SIT yard for lease to Sasol, KCSR will replace and expand its existing rail car classification yard in Mossville, La.
“KCS has been a key partner in ensuring safe and reliable delivery of our products to our customers for decades,” said Mike Thomas, senior vice president of U.S. operations for Sasol. “We are delighted to extend our relationship with KCS as we enhance the number and volume of products we manufacture at our Lake Charles site over the next several years.”
Kansas City Southern, through its auxiliaries, engages in the freight rail transportation business. It operates north/south rail route between Kansas City, Missouri, and various ports along the Gulf of Mexico in Alabama, Louisiana, Mississippi, and Texas in the midwest and southeast regions of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
